ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2022
Detailed approach toward the anti-hyperglycemic potential of Sterculia diversifolia G. Don against alloxan-induced in vivo hyperglycemia model.
Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate Sterculia diversifolia G. Don for potential anti-diabetic activity in the in vivo mouse model of alloxan-induced hyperglycemia.
methodsSterculia diversifolia (S. diversifolia) was subjected to extraction and isolation techniques and structural characterization of the isolated compounds were performed using spectroscopic methods. The acute toxicity test was performed by orally administering S. diversifolia in doses of 500-2000 mg/kg. For the assessment of anti-hyperglycemic activity, S. diversifolia bark and leaves extracts were administered orally in doses of 50, 100, and 200 mg/kg, along with metformin (150 mg/kg, i.p) as positive control, after confirmation of alloxan (150 mg/kg, i.p.) induced hyperglycemia in BALB/c mice. Serum biochemical parameters were monitored for the period of study.
resultsThe phytochemical studies showed the presence of quercetin and kaempferol in S. diversifolia. The IC50 values in the in vivo acute toxicity study revealed the safety margin of S. diversifolia bark (1166.66 mg/kg) and leaves (683.34 mg/kg) extracts. A significant attenuation of alloxan induced hyperglycemia was produced by S. diversifolia extracts at 50 mg/kg (P < 0.05), 100 mg/kg (P < 0.05, < 0.01), and 150 mg/kg (P < 0.05, < 0.01, < 0.001) during 1-4 h, which was comparable to metformin (P < 0.001). Significant (P < 0.001) improvement appeared in blood hemoglobin, protein, cholesterol, triglycerides, urea, creatinine, HDL, and LDL of the stem bark and leaves extracts treated diabetic mice.
conclusionThese findings connote the usefulness of S. diversifolia as an anti-diabetic in traditional medicine and this might be attributed to the presence of quercetin and kaempferol, among other phytochemicals.
Indexed as
Identifiers
35294118PMC10164638W4220805781What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.